MINIREVIEWS

Purine Salvage Pathways in the Intraerythrocytic Malaria Parasite
Plasmodium falciparum

Megan J. Downie,1,2 Kiaran Kirk,2 and Choukri Ben Mamoun1*

Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, Connecticut 06030,1 and School of Biochemistry and Molecular Biology, The Australian National University, Australian Capital Territory 0200, Australia2

Malaria is caused by protozoan parasites of the genus Plasmodium. Five species of Plasmodium cause infection in humans, with the majority of lethal cases caused by Plasmodium falciparum. This species is responsible for more than 500 million clinical cases of malaria each year (59). In the past 2 decades, efforts to combat this disease have been met with the emergence of widespread resistance to most of the commonly used antimalarial drugs (68). The poor efficacy of current drugs and the lack of a promising vaccine have resulted in alarming increases in the rates of malaria morbidity and mortality worldwide, with the major toll felt in the developing world.

P. falciparum is transmitted to humans via the bite of an infected female anopheline mosquito. In humans, the parasite undergoes one cycle of asexual multiplication in hepatocytes, followed by several cycles of infection and multiplication in red blood cells. Whereas the hepatocyte stage is asymptomatic, the erythrocytic stage is accompanied by the destruction of the host erythrocytes, resulting in anemia and, in the absence of treatment, death. Extensive efforts are presently under way to develop a vaccine, and advances in our understanding of the biology of the parasite and its metabolic and nutritional needs offer new routes for chemotherapy. In this regard, purine metabolism holds significant promise as a target for drug development.

It has long been recognized that protozoan parasites, including Plasmodium spp., are unable to synthesize purine rings de novo (4). Consistent with this observation, the sequencing of protozoan genomes has failed to uncover any genes encoding enzymes involved in the biosynthesis of purine nucleosides or nucleobases (12). Protozoan parasites rely instead on salvage of purines from the host. The strategies used in acquiring purines vary significantly among parasite genera. This review will focus primarily on the purine salvage pathways present in the Plasmodium parasite. Recent reviews have examined the metabolic pathways for purine salvage in other protozoa (11, 17, 29).

Initial studies on purine and pyrimidine synthesis in Plasmodium parasites were performed on erythrocytic stages of the rodent malaria species P. berghei (7, 8, 65), the macaque mon-
cell membrane, the parasitophorous vacuole membrane, and the parasite plasma membrane.

Nucleosides and nucleobases cross the host cell membrane via a combination of a high-affinity transport process and, in mature trophozoite-stage parasites, nonsaturatable, broad-specificity new permeability pathways induced by the parasite in the erythrocyte membrane (25, 26, 36, 37, 64). The high-affinity transport process is sensitive to inhibition by nitrobenzylthioinosine and probably represents transporters native to the erythrocyte membrane (25), such as human ENT1. The infected erythrocyte also displays the ability to transport t-enantiomers of nucleosides, and this uptake is inhibited by classical new permeability pathway blockers, such as furosemide and 5-nitro-2-(3-phenylpropylamino)benzoic acid (25, 27, 64). Once inside the infected erythrocyte, the nucleosides are presumed to cross the parasitophorous vacuole membrane via the large-diameter, nonselective pores present on this membrane (18).

From early work by Gero and colleagues, it was clear that the uptake of at least one nucleoside, the purine adenosine, across the parasite plasma membrane is extremely rapid (27, 64). In the first study of the functional expression of P. falciparum-encoded transporters in Xenopus laevis oocytes, cells injected with total mRNA from blood-stage parasites showed elevated transport of adenosine and hypoxanthine, consistent with the expression of one or more parasite-encoded nucleoside transporters (45); however, the proteins responsible were not identified. Subsequently, two independent studies reported the cloning of a P. falciparum nucleoside transporter, designated either P. falciparum NT1 (PfNT1) (10) or PfENT1 (44). In both cases, the protein was identified by searching for homologues of known nucleoside transporters in the P. falciparum genome sequence. The gene was cloned and expressed in Xenopus oocytes and shown to transport a range of nucleosides and nucleobases (10, 44). There were significant differences between the results of the two studies with regard to the reported characteristics of the transporter. Carter et al. (10) described the transporter (referred to hereafter as PfNT1) as having a high affinity for adenosine ($K_m = 13 \mu M$) and being sensitive to inhibition by 10 $\mu M$ dipyridamole, whereas Parker et al. (44) described it as having a much lower affinity for adenosine ($K_m = 320 \mu M$) and being insensitive to 10 $\mu M$ dipyridamole. These differences notwithstanding, it is clear that PfNT1 is a nucleoside transporter. In a subsequent study, Rager et al. used immunoelectron microscopy to obtain strong evidence that the protein is localized predominantly, if not exclusively, to the parasite plasma membrane (and not to the parasitophorous vacuole or host erythrocyte membrane) (51). Transport experiments on parasites isolated from their host cells by saponin treatment (which renders the host cell membrane freely permeable to macromolecules while leaving the parasite plasma membrane intact) revealed that nucleosides (20) and nucleobases (19) are transported across the parasite plasma membrane by a fast, low-affinity process, similar to that seen for the transport of these substrates by PfNT1 in Xenopus oocytes (19, 20). The absolute dependence of the parasite on PfNT1 expression was demonstrated in experiments by El Bismati and colleagues, in which it was shown that parasites harboring a genomic deletion of the PfNT1 gene ($pfnt1^\Delta$) were viable only when the purines adenosine, inosine or hypoxanthine were present at super-physiological concentrations (21).

While initial transport studies in $pfnt1^\Delta$ parasites (21) suggested that $pfnt1^\Delta$ parasites exhibited residual (PfNT1-independent) adenosine and inosine transport, further studies (taking into account the metabolic properties of the parasite) have shown that $pfnt1^\Delta$ parasites were unable to transport adenosine, inosine and hypoxanthine (21a). Further studies with this parasite strain have indicated that $pfnt1^\Delta$ parasites were unable to grow when guanine, guanosine, xanthine, or adenine were present at physiological concentrations (21a) and that $pfnt1^\Delta$ parasites were unable to transport guanine, guanosine, or xanthine but were able to transport adenosine, albeit at a lower rate (21a).

Recently, Quashie and colleagues have proposed the presence at the parasite plasma membrane of a high-affinity adenosine transport mechanism, which they have equated with PfNT1 (48). Their experimental design and subsequent interpretation of the data, however, do not take into consideration the rapid metabolism of purines, which is a high-affinity process. Taking into account the difficulties of distinguishing between transport and metabolism, a comprehensive analysis of all the available PfNT1 transport data (10, 19–21a, 44, 48) would suggest that PfNT1 is a low-affinity transporter that mediates the rapid uptake of adenosine, inosine, hypoxanthine, adenine, guanine, guanosine, and xanthine. There is some evidence that for adenine there is, in addition to PfNT1, a PfNT1-independent mechanism (21a, 48), yet to be characterized.

While available studies demonstrate an essential function for PfNT1, the completion of the P. falciparum genome sequencing project revealed three additional nucleoside transporters (PfNT2, PfNT3, and PfNT4) (24, 40). Like PfNT1, these proteins are expressed during the intraerythrocytic stage of the parasite life cycle as well as in gametocytes (5, 40, 70). Their cellular localization, as well as their role in parasite physiology, is yet to be elucidated.

**PURINE METABOLISM**

Studies of P. falciparum parasites isolated from host erythrocyte membranes by mechanical rupture showed the presence of the purine salvage enzymes adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP), and phosphoribosyltransferase (PRT) (52). Only minimal adenosine kinase activity was observed in this study (52). Subsequent studies have indicated that the parasite lacks adenosine kinase activity (55), and no adenosine kinase gene has been found in the genome (24). This is consistent with the idea that the majority of purine salvage occurs via the sequential conversion of adenosine and inosine to hypoxanthine, which is then phosphoribosylated to form IMP (52).

**P. FALCIPARUM ADENOSINE DEAMINASE**

The enzyme ADA catalyzes the irreversible hydrolytic cleavage of adenosine to produce inosine and ammonia. As native human ADA (hADA) activity is high in uninfected erythrocytes (15, 69), parasite-encoded ADA (PiADA) was initially characterized by infecting erythrocytes taken from a human donor genetically deficient in ADA with P. falciparum (15). Parasite growth levels were comparable in normal and defi-
cient host cells, and infected deficient host cells exhibited a level of ADA activity twice that seen in normal, uninfected erythrocytes. The ADA activity in parasite protein preparations exhibited essentially the same $K_m$ for adenosine as the ADA activity in protein preparations from uninfected, normal erythrocytes (15). Both erythrocyte and parasite ADA enzymes are inhibited by nanomolar concentrations of deoxycoformycin (15). PIADA, however, has a much lower sensitivity than hADA to the inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (15). Recombinant PIADA (expressed in Escherichia coli) has a $K_m$ of 11 ± 2 μM for adenosine (22), a figure similar to that reported for free $P. falciparum$ parasite lysates (7 μM) (6) and to that seen for lysates from the duck parasite $P. lophurae$ (23 μM) (69). The $P. falciparum$ enzyme is also reportedly sensitive to two $\lambda$-nucleoside structural analogues of deoxy-$\alpha$-coformycin that have no effect on hADA (6) as well as to 5'-methylthio coformyclics (as detailed below) (63).

**P. Falciparum Purine Nucleoside Phosphorylase**

PNP enzymes are responsible for the phosphorylation of nucleosides into the corresponding nucleobases and ribose groups. This reaction is reversible and is carried out in the presence of inorganic phosphate (9). There are two major families of nucleoside phosphorylases: the low-molecular-mass homotrimers, which include all mammalian PNPs and some bacterial PNPs, and the high-molecular-mass homohexamers, which include most bacterial PNPs, along with mammalian and bacterial uridine phosphorylases (9). Most PNPs contain consensus sequences specific to the relevant family (33). Initial studies of $P. falciparum$ PNP (PfPNP; utilizing red blood cells taken from a child deficient in PNP) (16) showed that PfPNP is capable of utilizing inosine, guanosine, and deoxyguanosine but not adenosine or xanthosine. Expression of the gene encoding PfPNP in $E. coli$ revealed that PfPNP is not a typical member of either of the two major classes of PNPs, having low sequence homology and a distinct substrate specificity to PNPs from other species (33). The purified enzyme has a $K_m$ for inosine of 5.0 ± 0.9 μM and can be inhibited by immucilins with dissociation constants as low as 0.6 nM (33). Immucilins are PNP transition state analogues, some of which have $K_i$ values as low as 7 pM (54). Immucillin-H is currently in clinical trials for treating human T-cell malignancies (23, 54) and has been shown to inhibit PfPNP, as well as inhibiting $P. falciparum$ growth, in vitro (33, 34). This in vitro inhibition of parasite growth can be reversed by the addition of hypoxanthine, but not inosine, to the culture medium, indicating that PfPNP is the target for this drug (34).

**PIADA and PiPNP Utilize Unique Substrates**

The crystal structure of PiPNP in complex with immucillin-H revealed a homo-hexamer, organized as a trimer of dimers, with an immucillin-H molecule bound at each of the catalytic sites (58). The structure also revealed that the catalytic site has a capacity for binding 5'-substituted nucleosides, and kinetic studies have confirmed that 5'-methylthioinosine (MTI) is a good substrate for PiPNP, being converted to hypoxanthine, indicating that this protein has dual catalytic func-

**PiADA and PiPNP as Drug Targets**

The abilities of PiADA and PiPNP to recognize methylthio-substituted purines led to the development of 5'-methylthio coformyclics (63) and methylthio–immucillin-H (MT–immucillin-H) (60). The 5'-methylthio coformyclics inhibit PiADA at very low concentrations but do not inhibit hADA (63). The abilities of these compounds to inhibit parasite growth in the presence of physiologically relevant concentrations of inosine and hypoxanthine remain to be established. The validity of ADA as an antiplasmodial target is questionable, however. While early studies showed that 2'-deoxycoformycin can clear an in vivo $P. knowlesi$ infection (67), the in vitro growth of $P. falciparum$ was not inhibited by 10 μM 2'-deoxycoformycin, despite complete inhibition of (both host and parasite) ADA enzyme activity at this concentration (15, 53). Whether this discrepancy is due to species-specific differences or due to in vitro culture conditions is unknown.

The addition of a 5'-methylthio group to immucillin-H allows the preferential binding of MT–immucillin-H to PiPNP over human PNP (hPNP) by a factor of 112 (58). MT–immucillin-H kills $P. falciparum$ in vitro with a 50% inhibitory concentration of 50 nM, compared to a 50% inhibitory concentration of 63 nM for immucillin-H (60). It should be noted, however, that these values were derived from inhibition curves carried out with culture media containing no hypoxanthine, under which conditions parasite growth would be completely reliant upon PNP activity (60).

The potential of PiADA and PiPNP as therapeutic targets is yet to be validated by genetic means. While the extent to which purine concentrations fluctuate in mammalian blood is unknown and the amounts of adenosine, inosine, and hypoxanthine available in human plasma are a source of contention, several groups report that hypoxanthine is the major purine available in human serum in vivo (42, 62). Therefore, it seems likely that a block in the purine salvage pathway at the ADA or PNP step could be circumvented by the downstream salvage of hypoxanthine, guanine, or xanthine from the host, all of which are transported into the parasite by PfNT1 and phosphoribosylated by $P. falciparum$ hypoxanthine-guanine-xanthine PRT (PiHGXPRT). There is a clear need for in vitro studies in which the serum concentrations of all purines are replicated or, ideally, in vivo animal studies on the effects of these compounds on $Plasmodium$ growth. Despite the fact that recom-
Toxoplasma gondii PNP is sensitive to immucillin-H, the in vitro growth of the parasite is unaffected due to the presence of a redundant purine salvage pathway (the direct phosphorylation of adenosine by adenosine kinase). While T. gondii parasites deficient in adenosine kinase are sensitive to immucillin-H, this sensitivity can be rescued by addition of hypoxanthine to the medium (13).

P. FALCIPARUM PHOSPHORIBOSYLTRANSFERASE ENZYMES

Nucleobases can be converted directly to nucleoside monophosphates by the action of PRT enzymes. PRT enzymes catalyze the reversible transfer of a phosphoribosyl group from phosphoribosylpyrophosphate to a nucleobase, resulting in the production of a nucleotide and pyrophosphate (14). In P. falciparum, PRT activity is catalyzed by a single enzyme, HGXPRT (49), while a second enzyme was shown to account for adenine PRT (APRT) activity (Fig. 1) (50), as is the case for mammalian cells. The ability of the enzyme to utilize xanthine as a substrate distinguishes PfHGXPRT from its counterpart enzyme in the human red blood cell. Although P. falciparum has only low levels of APRT activity (high-performance liquid chromatography data indicated that the amount of HGXPRT activity is about 1,500 times greater than that present for APRT) (50), this activity does exhibit properties that differ from those of the APRT present in human erythrocytes. These include a lower apparent molecular weight and a differing inhibition profile (50). Studies on duck erythrocytes infected with P. lophurae indicated that the avian...
parasite also has APRT activity with kinetic properties different from those of the host cell APRT enzyme \((\text{Plasmodium} K_m = 3.4 \text{ M}, \text{host } K_m = 69 \text{ M})\) (69). Pollack and colleagues (47) reported the cloning of \(P. falciparum\) APRT, although the gene sequence was not determined. Mouse cell lines transfected with this gene exhibited APRT activity with a \(K_m\) value similar to that seen for lysates from isolated \(P. falciparum\) (47). However, the presence of APRT activity in \(P. falciparum\), \(Eimeria\), or \(Cryptosporidium\) spp. (12). Although wild-type parasites are able to grow on adenine as a sole purine source, \(pfnt1\) parasites are unable to complete the intraerythrocytic life cycle on physiological concentrations of adenine, despite measurable uptake of adenine by saponin-isolated \(pfnt1\) parasites (21a). This suggests either that all adenine is converted in the red blood cell such that the parasite cytosol never sees adenine or that adenine cannot be metabolized by the parasite, a hypothesis consistent with the suggestion that the parasite lacks an APRT enzyme.

The PfHGXPRT enzyme displays high activity for all three purine substrates, with some variation in affinity for them \((K_m\) of hypoxanthine = 0.46 M, \(K_m\) of guanine = 0.30 M, and \(K_m\) of xanthine = 9.4 M) (49). King and Melton reported the first cloning and sequencing of PfHGXPRT (35). When expressed in \(E. coli\) (31), the recombinant enzyme was shown to differ from the human enzyme in several respects, including an increased ability to utilize allopurinol as a substrate. There are many good inhibitors of PRT enzymes, including phosphorylated versions of the previously described immucillins (e.g., immucillin-HP and immucillin-GP). The cell permeability of phosphorylated inhibitors is, however, an obvious concern. The available crystal structures of PfHGXPRT (56) and human

**FIG. 2.** Nucleotide production in \(P. falciparum\). Hypoxanthine, which is both transported into the cytoplasm from plasma and produced from adenosine and inosine metabolism (indicated by multiple arrows; see Fig. 1 for more detail), is converted to IMP by PfHGXPRT. IMP can then be converted to adenylate or guanylate nucleotides. To make adenylate nucleotides, IMP is converted to adenylsuccinate by adenylsuccinate synthetase. Adenylsuccinate lyase then converts adenylsuccinate to AMP. AMP is phosphorylated to ADP (by adenylyl kinase). Alternatively, IMP can be converted to XMP by IMP dehydrogenase. XMP (which can also be produced directly from xanthine by PfHGXPRT) is converted to GMP by GMP synthetase. GMP can also be produced from guanine by PfHGXPRT. Guanylate kinase phosphorylates GMP to form GDP. Both GDP and ADP are then converted to the NTP or deoxynucleoside triphosphates used in nucleic acid synthesis. PRPP, phosphoribosylpyrophosphate; RBC, red blood cell; PV, parasitophorous vacuole.
HGPRT (57), each in complex with these compounds, should aid in the design of species-specific inhibitors (38). Recently, several purine nucleobase analogues were identified that, while being good substrates for PfHGPRT, were comparatively weak substrates for the human enzyme (32). The discovery of compounds that can interact preferentially with the parasite enzyme, together with the reported lack of nucleobase phosphoribosylation redundancy in *P. falciparum*, makes PfHGPRT a promising target for the development of antimalarial therapies.

**NUCLEOTIDE PRODUCTION**

As detailed above, the great majority of purines salvaged by *P. falciparum* are funneled through hypoxanthine to IMP. To generate adenylate nucleotides within the parasite, IMP is first converted to adenosine by adenosine synthetase, which is then converted by adenosine deaminase to AMP. IMP dehydrogenase converts IMP to XMP, which is then converted to GMP by GMP synthetase (41). A recent biochemical characterization of this enzyme suggests that it differs from its mammalian counterpart on several levels, including differences in ligand specificity (3). HGXPRT can also convert xanthine base directly to XMP and guanine base to GMP. AMP and GMP are then converted to the final nucleotides used in nucleic acid synthesis (Fig. 2).

**SUMMARY**

Purines enter the intraerythrocytic malaria parasite via a fast, low-affinity, broad-capacity process that can be attributed primarily to the parasite plasma membrane transporter PfNT1. The reliance of the parasite on PfNT1 makes this protein a primary channel on the intraerythrocytic malaria parasite. Nature 2006. The plasma membrane permease PfNT1 is essential for parasite growth in a serum-free medium. Parasitology 113: 19–23.

**REFERENCES**

1. Asahi, H., T. Kanazawa, Y. Kajihara, K. Takahashi, and T. Takahashi. 1996. Hypoxanthine: a low molecular weight factor essential for growth of erythrocytic *Plasmodium falciparum* in a serum-free medium. Parasitology 113: 19–23.

2. Baldwin, S. A., G. A. McConkey, C. E. Cass, and J. D. Young. 2007. Nucleoside transport as a potential target for chemotherapy in malaria. Curr. Top. Med. Chem. 7:1569–75.

3. Bhat, J. Y., B. G. Shastri, and H. Balararam. 2008. Kinetic and biochemical characterization of *Plasmodium falciparum* GMP synthetase. Biochem. J. 409:263–73.

4. Booden, T., and R. W. Hull. 1973. Nucleic acid precursor synthesis by *Plasmodium knowlesi* parasitizing chicken erythrocytes. Exp. Parasitol. 24:220–22.

5. Bozdech, Z., M. Llinas, B. L. Pulliam, E. D. Wong, J. Zhu, and J. L. DeRisi. 2003. The transcriptome of the intraerythrocytic developmental cycle of *Plasmodium falciparum*. PLoS Biol. 1:4E5.

6. Brown, D. M., A. G. Netting, B. K. Chun, Y. Choi, C. K. Chu, and A. M. Ger0. 1999. L-nucleoside analogues as potential antimalarials that selectively target *Plasmodium falciparum* adenosine deaminase. Nucleosides Nucleotides Nucleic Acids 18:2521–2532.

7. Bungener, W., and G. Nielsen. 1967. Nucleic acid metabolism in experimental malaria. I. Studies on the incorporation of thymidine, uridine, and adenosine in the malaria parasite (*Plasmodium berghei* and *Plasmodium vinckei*). Z. Tropenmed. Parasitol. 18:456–462. (In German.)

8. Burgener, W., and G. Nielsen. 1968. Nucleic acid metabolism in experimental malaria. II. Incorporation of adenine and hypoxanthine into the nucleic acids of malaria parasites (*Plasmodium berghei* and *Plasmodium vinckei*). Z. Tropenmed. Parasitol. 19:185–197. (In German.)

9. Brown, D. M., A. G. Netting, B. K. Chun, and D. Shugar. 2000. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol. Ther. 88: 349–425.

10. Carter, N. S., C. Ben Mamoun, W. Liu, E. O. Silva, S. M. Landfear, D. E. Goldberg, and B. Ullman. 2000. Isolation and functional characterization of the PfNT1 nucleoside transporter gene from *Plasmodium falciparum*. J. Biol. Chem. 275:10683–10691.

11. Carter, N. S., P. Yates, C. S. Arendt, J. M. Boitz, and B. Ullman. 2004. Purine and pyrimidine metabolism in Leishmania. Adv. Exp. Med. Biol. 625:141–154.

12. Chaudhary, K., J. A. Darling, L. M. Fohl, W. J. Sullivan, Jr., R. G. Donald, E. R. Pfefferkorn, B. Ullman, and D. S. Roos. 2004. Purine salvage pathways in the apicomplexan parasite *Toxoplasma gondii*. J. Biol. Chem. 279:31221–31227.

13. Chaudhary, K., L. M. Ting, K. Kim, and D. S. Roos. 2006. *Toxoplasma gondii* purine nucleoside phosphorolysis biochemical characterization, inhibitor profiles, and comparison with the *Plasmodium falciparum* ortholog. J. Biol. Chem. 281:25652–25658.

14. Craig, S. G., III, and A. E. Eakin. 2000. Purine phosphorylases are essential for growth of *Plasmodium falciparum* in culture. J. Biol. Chem. 275:20231–20234.

15. Daddona, P. E., W. P. Wiesmann, C. Lambros, W. N. Kelley, and H. K. Webster. 1984. Human malaria parasite adenosine deaminase. Characterization in host enzyme-deficient erythrocyte culture. J. Biol. Chem. 259:1472–1475.

16. Daddona, P. E., W. P. Wiesmann, W. Milhouse, J. W. Chern, L. B. Townsend, M. S. Hershfield, and H. K. Webster. 1986. Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors. J. Biol. Chem. 261:11667–11673.

17. de Koning, H. P., D. J. Bridges, and R. J. Burchmore. 2005. Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy. FEMS Microbiol. Rev. 29:987–1020.

18. Desai, S. A., D. J. Krogstad, and E. W. McCluskey. 1993. A nutrient-permeable channel on the intraerythrocytic malaria parasite. Nature 362:643–646.

19. Downie, M. J., K. J. Saliba, S. Broer, S. M. Howitt, and K. Kirk. 2008. Purine nucleobase transport in the intraerythrocytic malaria parasite. Int. J. Parasitol. 38:203–209.

20. Downie, M. J., K. J. Saliba, S. M. Howitt, S. Broer, and K. Kirk. 2006. Transport of nucleosides across the *Plasmodium falciparum* plasma membrane has characteristics of PfENT1. Mol. Microbiol. 60:738–748.

21. El Bissati, K., R. Zafferey, W. H. Witolu, N. S. Carter, B. Ullman, and C. Ben Mamoun. 2006. The plasma membrane permease PfNT1 is essential for parasite growth in the human malaria parasite *Plasmodium falciparum*. Proc. Natl. Acad. Sci. USA 103:9286–9291.

22. El Bissati, K., M. J. Downie, S.-K. Kim, M. Horowitz, N. Carter, B. Ullman, and C. Ben Mamou. 3 July 2008. Genetic evidence for the essential role of PfNT1 in the transport and utilization of xanthine, guanine, guanosine and adenine by *Plasmodium falciparum*. Mol. Biochem. Parasitol. doi:10.1016/j.molbiopara.2008.06.012.

23. Engelhardt, B. E., M. I. Jordan, K. E. Muratore, and S. E. Brenner. 2005. Protein molecular function prediction by bayesian phylogenomics. PLoS Comput. Biol. 1:e45.

24. Gandhi, V., J. M. Kilpatrick, W. Plunkett, M. Ayres, L. Harman, M. Du, S. Bantia, J. Davison, W. G. Wierda, S. Faderl, H. Kantarjian, and D. Thomas. 2005. A proof-of-principle pharmacokinetic, pharmacodynamic,
and clinical study with a nucleoside phosphorylase inhibitor immunoligand.” Blood 106:4235–4260.
24. Gardner, M. J., N. Hall, E. Fung, O. White, M. Berriman, R. W. Hyman, J. M. Carlton, A. Pain, K. E. Nelson, S. Bowman, I. T. Paulsen, K. James, J. A. Eisen, K. Rutherford, S. D. Salzberg, A. Craig, S. Kyes, M. S. Chan, V. Nene, S. J. Shalloom, B. Suh, J. Peterson, S. Anginolu, M. Pertea, J. Allen, J. Selengut, D. Haft, M. W. Mather, A. B. Vaidya, D. M. Martin, A. H. Fairlamb, M. J. Frauenholz, D. S. Roos, S. A. Ralph, G. I. McFadden, L. M. Cuningham, J. A. Shromman, C. Mungall, J. C. Venier, D. J. Curnier, S. L. Hoffman, C. Newbold, R. W. Davis, C. M. Fraser, and B. Barrell. 2005. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419:98–111.
25. Shi, W., A. Lin, T. I. Wang, J. D. Young, and A. R. Paterson. 1990. Parasite-induced processes for adenosine permeation in mouse erythrocytes infected with the malarial parasite Plasmodium yoelii. Biochem. J. 272:277–280.
26. Gero, A. M., E. M. Bugledich, A. R. Paterson, and G. P. Jamieson. 1988. Stage-specific alteration of nucleoside membrane permeabilities and nitrobenzoxylthionine insensitivity in Plasmodium falciparum infected erythrocytes. Mol. Biochem. Parasitol. 27:159–170.
27. Gero, A. M., and S. T. Hall. 1997. Plasmodium falciparum: transport of enantiomers of nucleosides into Sendai-treated trophotzoites. Exp. Parasitol. 68:226–231.
28. Gutteridge, W. E., and P. I. Trigg. 1970. Incorporation of radioactive precursors into DNA and RNA of Plasmodium knowlesi in vitro. J. Protozool. 17:90–96.
29. Hyde, J. E. 2007. Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr. Drug Targets 8:313–471.
30. Jayalakshmi, R., K. Sumathy, and H. Balaram. 1994. Characterisation of cDNA clones for adenylate deaminase from Plasmodium berghei. J. Biol. Chem. 269:3339–3347.
31. Lauer, S. A., P. K. Rathod, N. Ghori, and K. Haldar. 2002. Purification and characterization of Plasmodium falciparum adenylate deaminase plant products in Plasmodium falciparum. Mol. Biochem. Parasitol. 98:29–41.
32. Kaur, D. T., A. L. Ng, D. J. Winzor, B. T. Emmerson, and J. de Jersey. 1999. Purification and characterisation of Plasmodium falciparum hypoxanthine-guanine-phosphoribosyltransferase and comparison with the human enzyme. Mol. Biochem. Parasitol. 93:29–41.
33. King, A., and D. W. Melton. 1997. Hypoxanthine-guanine phosphoribosyltransferase from the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol. 80:1–22.
34. Krishna, N., B. D. Durin-Semblat, P. G. Bray, G. A. Biagini, C. Doerig, L. C. Ransford-Cartwright, and H. P. De Koning. 2008. A comprehensive model of parasite uptake by the malaria parasite Plasmodium falciparum: identification of four parasite transport activities in intracellular trypanosomatid parasites. Biochem. J. 411:287–295.
35. Queen, S. A., D. Vander Jagt, and P. Reyes. 1988. Properties and substrate specificity of a purine phosphorylase transferase from the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol. 30:123–133.
36. Queen, S. A., D. Vander Jagt, and P. Reyes. 1989. Characterisation of adenine phosphorylase transferase from the human malaria parasite, Plasmodium falciparum. Biochem. Biophys. Acta 996:160–165.
37. Rager, N., C. B. Mamoun, N. S. Carter, D. E. Goldberg, and B. Ullman. 2001. Localization of the Plasmodium falciparum PINT1 nucleoside transporter to apical apical parasite. Mol. Biochem. Parasitol. 127:275–290.
38. Roth, E., Jr., N. Ogasawara, and S. Schulman. 1989. The deamination of adenosine and adenosine monophosphate in Plasmodium falciparum-infected human erythrocytes: in vitro use of 2′-deoxycoformycin and AMP deaminase-deficient red cells. Blood 74:1121–1125.
39. Schramm, V. L., P. C. Tyler, and B. T. Emmerson. 1994. Conversion of T-cell proliferation and malaria. Nucleosides Nucleotides Nucleic Acids 23:1305–1311.
40. Sherman, I. W. 1998. Purine and pyrimidine metabolism of asexual stages, p. 177–184. In I. W. Sherman (ed.), Malaria: parasite biology, pathogenesis and protection. ASM Press, Washington, DC.
41. Shi, W., C. M. Li, P. C. Tyler, R. H. Furneaux, S. M. Cahill, M. E. Girvin, C. Grubmeyer, V. L. Schramm, and S. C. Almo. 1999. The 2.0 A structure of malarial purine phosphorylase transfers in complex with a transition-state analog inhibitor. Biochemistry 38:9872–9880.
42. Shi, W., C. M. Li, P. C. Tyler, R. H. Furneaux, C. Grubmeyer, V. L. Schramm, and S. C. Almo. 1999. The 2.0 A structure of human hypoxanthine-guanine phosphorylase transfers in complex with a transition-state analog inhibitor. Nat. Struct. Biol. 6:598–598.
43. Snow, R. W., C. A. Guerra, A. M. Noor, H. Y. Myint, and S. I. Hay. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214–217.
44. Tracy, S. M., and I. W. Sherman. 1972. Purine uptake and utilization by the avian malaria parasite Plasmodium lophurae. J. Protozool. 19:541–549.
45. Tran, T. W. 1994. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140:1–22.
46. Tyler, P. C., E. A. Taylor, R. F. Frohlich, and V. L. Schramm. 2007. Synthesis of 5′-methylythio coformicin: specific inhibitors for malarial adenosine deaminase. J. Am. Chem. Soc. 129:8872–8879.
47. Upston, J. M., and A. M. Gero. 1994. Purine-induced permeation of nucleo- sides in Plasmodium falciparum malaria. Biochem. Biophys. Acta 1236:249–258.
48. Van Dyke, K., G. C. Trembly, C. H. Lantz, and C. Szustkiewicz. 1970. The source of adenine and pyrimidines in Plasmodium berghei. Am. J. Trop. Med. Hyg. 19:202–208.
49. Walsh, J. C., and I. W. Sherman. 1968. Purine and pyrimidine synthesis by the avian malaria parasite Plasmodium lophurae. J. Protozool. 15:763–770.
50. Webster, H. K., W. P. Wiesman, and C. S. Pavia. 1984. Adenosine deaminase in malaria infection: effect of dodecylamine. J. Biol. Chem. 259:9047–9054.
51. Tracy, S. M., and I. W. Sherman. 1972. Purine uptake and utilization by the avian malaria parasite Plasmodium lophurae. J. Protozool. 19:541–549.
52. Tran, T. W. 1994. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140:1–22.